艾普拉唑联合瑞巴派特治疗消化性溃疡的疗效及安全性研究

Efficacy and safety of ilaprazole enteric-coated tablets combined with rebamipide tablets in the treatment of peptic ulcer

目的观察艾普拉唑联合瑞巴派特治疗消化性溃疡的疗效以及安全性。方法采用电脑随机化抽样方法将100例消化性溃疡病人分为两组,其中对照组50例,脱选2例;观察组50例,脱选1例,两组均未出现剔除病例。对照组给予艾普拉唑口服治疗;观察组给予艾普拉唑加瑞巴派特口服治疗。所有病人均治疗4周,比较两组病人治疗前后临床症状评分;比较内镜下疗效以及不良反应发生情况。结果治疗前两组病人临床症状评分比较差异无统计学意义(P>0.05),治疗后,两组病人评分均明显下降,其中以观察组更加显著,差异有统计学意义(P<0.05);两组病人在研究结束后进行内镜检查并判断疗效,观察组的治疗总有效率为95.9%,显著优于对照组的79.2%(P<0.05);两组病人均未出现显著的危害性不良反应。结论艾普拉唑联合瑞巴派特治疗消化性溃疡,较单一使用艾普拉唑治疗消化性溃疡,不仅溃疡愈合质量高,而且安全可靠,值得临床应用和推广。

Objective To study the efficacy and safety of ilaprazole enteric-coated tablets combined with rebamipide tablets in the treatment of peptic ulcer.Methods100patients of peptic ulcer were randomly divided into two groups,50patients in the control group and there were two patients exclude and50patients in the experimental group while the one patient was excluded.The control group received ilaprazole enteric-coated tablets orally.And the experimental group received ilaprazole enteric-coated tablets in combination with rebamipide tablets.All the patients were treated for4weeks.To compare the curative effect,the clinical symptom scores of the two groups and endoscopy tests were performed before and after the treatment.Results There was no significant difference in clinical symptom scores between the two groups before treatment(P>0.05).After treatment,the scores of the two groups decreased significantly(P<0.05)especially the experimental group.The effective rate of the experimental group was95.9%,significantly higher than that of the control group(79.2%,P<0.05).No severe adverse reactions occurred in the two groups.Conclusion Ilaprazole enteric-coated tablets combined with rebamipide tablets not only has better efficacy than ilaprazole alone in the treatment of peptic ulcer,but also with safety and reliability,worthy clinical application and promotion.